2.2. Patient Enrollment
diabetes mellitus, allergy, phimosis, tumors, UTIs
CHRONIC PROSTATITIS, URETHRAL STRICTURES, CARCINOMA IN SITU, INTERSTITIAL CYSTITIS, DIABETES MELLITUS, ALLERGY, URINARY INCONTINENCE, MEATAL STENOSIS, DIFFICULTY SWALLOWING, IMMUNODEFICIENCY DISORDERS, BLADDER STONES, TUMORS, NEUROGENIC BLADDER
Patients undergoing cystoscopy for suspected BCa or follow-up after transurethral resection of the bladder (TURB), with negative urine culture, were enrolled. The exclusion criteria were: bladder catheter present or removed in the last 30 days; bladder stones; diagnostic or therapeutic endoscopic procedures on the urinary tract (including TURB) in the last 3 months; bladder biopsy during cystoscopy; intravesical therapy for BCa in the last 30 days; history of interstitial cystitis, recurrent UTIs, or chronic prostatitis; presence of urethral strictures, meatal stenosis, urinary incontinence, neurogenic bladder, or severe phimosis; history of carcinoma in situ or muscle invasive tumors not undergoing radical cystectomy; immunodeficiency disorders; uncompensated diabetes mellitus (HbA1c > 7%); allergy to substances evaluated in the study; and difficulty swallowing tablets.